Chemistry:Eratrectinib

From HandWiki

Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC.[1][2]

It has been approved in June 2026 for use in treating for solid tumors in China.[3]

References

  1. ↑ "Eratrectinib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800061132. 
  2. ↑ "Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study". Experimental Hematology & Oncology. June 2026. doi:10.1186/s40164-026-00799-9. PMID 42351304. 
  3. ↑ "NMPA Approves Vcare's Eratrectinib for NTRK Tumors". 5 June 2026. https://allsci.com/news/approvals/chinas-nmpa-approves-vcare-pharmatechs-eratrectinib-for-ntrk-fusion-positive-solid-tumors/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Eratrectinib&oldid=4583221"